A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT05521191 PHASE1 COMPLETED

Primary Objectives * To assess the safety and tolerability of RGLS8429 * To assess the impact of RGLS8429 on ADPKD biomarkers Secondary Objectives * To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV) * To characterize the pharmacokinetic (PK) properties of RGLS8429 * To assess the impact of RGLS8429 on renal function

Details

Lead sponsor	Regulus Therapeutics Inc.
Phase	PHASE1
Status	COMPLETED
Enrolment	68
Start date	Thu Oct 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Mar 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Autosomal Dominant Polycystic Kidney Disease
• ADPKD
• Polycystic Kidney, Autosomal Dominant

Interventions

• RGLS8429
• Placebo

Countries

United States